Marco Ruella

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9241085/publications.pdf

Version: 2024-02-01

122 papers	7,947 citations	109321 35 h-index	53230 85 g-index
123 all docs	123 docs citations	123 times ranked	8335 citing authors

#	Article	IF	Citations
1	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery, 2015, 5, 1282-1295.	9.4	997
2	Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology, 2020, 38, 947-953.	17.5	692
3	Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. Journal of Clinical Investigation, 2016, 126, 3814-3826.	8.2	472
4	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, 2018, 24, 1499-1503.	30.7	459
5	Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptorâ€“modified T cells. Blood, 2014, 123, 2343-2354.	1.4	396
6	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, 127, 1117-1127.	1.4	381
7	CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia, 2015, 29, 1637-1647.	7.2	343
8	Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell, 2018, 173, 1439-1453.e19.	28.9	323
9	Emerging Cellular Therapies for Cancer. Annual Review of Immunology, 2019, 37, 145-171.	21.8	263
10	Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Computational and Structural Biotechnology Journal, 2016, 14, 357-362.	4.1	229
11	Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight, 2018, 3, .	5.0	191
12	Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. Cancer Discovery, 2020, 10, 552-567.	9.4	184
13	Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. New England Journal of Medicine, 2021, 384, 673-674.	27.0	178
14	An NK-like CAR TÂcell transition in CAR TÂcell dysfunction. Cell, 2021, 184, 6081-6100.e26.	28.9	160
15	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research, 2016, 22, 2684-2696.	7.0	157
16	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery, 2017, 7, 1154-1167.	9.4	149
17	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood, 2017, 129, 2395-2407.	1.4	148
18	Immunogenicity of CAR T cells in cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 379-393.	27.6	128

#	Article	IF	Citations
19	Adoptive immunotherapy for cancer. Immunological Reviews, 2014, 257, 14-38.	6.0	119
20	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine, 2022, 28, 713-723.	30.7	117
21	Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia, 2017, 31, 246-248.	7.2	106
22	Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. BioDrugs, 2017, 31, 473-481.	4.6	105
23	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature Medicine, 2021, 27, 842-850.	30.7	88
24	Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas. Blood, 2018, 132, 4198-4198.	1.4	71
25	The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy, 2020, 22, 57-69.	0.7	70
26	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood, 2022, 139, 1026-1038.	1.4	67
27	Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget, 2018, 9, 25764-25780.	1.8	61
28	Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. Current Hematologic Malignancy Reports, 2016, 11, 368-384.	2.3	60
29	Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. Current Hematologic Malignancy Reports, 2017, 12, 522-529.	2.3	60
30	The aging effect of chemotherapy on cultured human mesenchymal stem cells. Experimental Hematology, 2011, 39, 1171-1181.	0.4	59
31	Born to survive: how cancer cells resist CAR T cell therapy. Journal of Hematology and Oncology, 2021, 14, 199.	17.0	59
32	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. American Journal of Hematology, 2014, 89, 306-309.	4.1	50
33	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British Journal of Haematology, 2014, 167, 541-546.	2.5	47
34	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Frontiers in Immunology, 2020, 11, 888.	4.8	45
35	Chimeric Antigen Receptor T-cell Therapy to Target Hematologic Malignancies. Cancer Research, 2014, 74, 6383-6389.	0.9	38
36	Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing. Clinical Cancer Research, 2021, 27, 6298-6306.	7.0	37

#	Article	IF	Citations
37	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 783-791.	0.8	35
38	The current landscape of single-cell transcriptomics for cancer immunotherapy. Journal of Experimental Medicine, 2021, 218, .	8.5	35
39	Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica, 2021, 106, 1705-1713.	3.5	34
40	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. Blood, 2016, 128, 652-652.	1.4	31
41	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. Blood Cancer Discovery, 2022, 3, 103-115.	5.0	31
42	Lymphocyte transformation and autoimmune disorders. Autoimmunity Reviews, 2013, 12, 802-813.	5.8	26
43	Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, S19-S21.	2.0	26
44	A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptorâ€“positive cells. Blood, 2020, 135, 505-509.	1.4	25
45	How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opinion on Biological Therapy, 2015, 15, 761-766.	3.1	24
46	Myeloablative doses of yttriumâ€90â€ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. Cancer, 2011, 117, 5074-5084.	4.1	23
47	Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless ofÂhydroxycarbamide therapy. Experimental Hematology, 2013, 41, 627-634.	0.4	22
48	Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation. Hepatology International, 2013, 7, 1075-1083.	4.2	21
49	Novel Immunotherapies for T Cell Lymphoma and Leukemia. Current Hematologic Malignancy Reports, 2018, 13, 494-506.	2.3	21
50	Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nature Communications, 2022, 13, .	12.8	21
51	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Annals of Hematology, 2013, 92, 1503-1511.	1.8	19
52	Bone marrow-derived cell mobilization by G-CSF to enhance osseointegration of bone substitute in high tibial osteotomy. Knee Surgery, Sports Traumatology, Arthroscopy, 2013, 21, 237-248.	4.2	18
53	Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkinâ€™s Lymphoma: Correlation with Long-Term Survival. PLoS ONE, 2014, 9, e106745.	2.5	18
54	Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model. Biology of Blood and Marrow Transplantation, 2017, 23, S19-S20.	2.0	17

#	Article	IF	Citations
55	CARâ€T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. British Journal of Haematology, 2021, 193, 449-465.	2.5	17
56	Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR. Blood, 2016, 128, 281-281.	1.4	16
57	Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors. Blood, 2019, 134, 622-622.	1.4	15
58	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. Bone Marrow Transplantation, 2010, 45, 505-512.	2.4	14
59	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose ⁹⁰Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. Journal of Clinical Oncology, 2013, 31, 2974-2976.	1.6	14
60	Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. Molecular Therapy, 2018, 26, 1401-1403.	8.2	14
61	A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy. Blood, 2019, 134, 4108-4108.	1.4	14
62	Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity. Blood, 2015, 126, 565-565.	1.4	14
63	Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. Blood, 2015, 126, 852-852.	1.4	13
64	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT /Overlock		12
65	Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas. Blood, 2019, 134, 1606-1606.	1.4	12
66	Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience. Blood, 2019, 134, 3240-3240.	1.4	11
67	Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy. Blood, 2019, 134, 247-247.	1.4	11
68	Adoptive T-cell therapy for Hodgkin lymphoma. Blood Advances, 2021, 5, 4291-4302.	5.2	11
69	Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. Leukemia and Lymphoma, 2018, 59, 2040-2055.	1.3	10
70	Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. , 2021, 9, e001514.		10
71	Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient. Kidney Medicine, 2021, 3, 665-668.	2.0	10
72	Abstract 4575: Chimeric antigen receptor macrophages (CARMA) for adoptive cellular immunotherapy of solid tumors. Cancer Research, 2017, 77, 4575-4575.	0.9	10

#	Article	IF	Citations
73	Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma. Blood, 2014, 124, 806-806.	1.4	10
74	Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models. Blood, 2013, 122, 143-143.	1.4	9
75	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Blood, 2016, 128, 43-43.	1.4	9
76	Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells. Blood, 2016, 128, 766-766.	1.4	9
77	18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Molecular Imaging and Biology, 2021, 23, 818-826.	2.6	8
78	Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms. Blood, 2016, 128, 2159-2159.	1.4	8
79	Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells. Frontiers in Oncology, 2019, 9, 568.	2.8	7
80	Combination of Anti-CD123 and Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment and Prevention of Antigen-Loss Relapses Occurring after CD19-Targeted Immunotherapies. Blood, 2015, 126, 2523-2523.	1.4	7
81	Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. Annals of Translational Medicine, 2016, 4, 13.	1.7	7
82	Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors. Blood, 2021, 138, 1727-1727.	1.4	7
83	CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL. Blood, 2021, 138, 469-469.	1.4	7
84	Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia. Blood Coagulation and Fibrinolysis, 2012, 23, 331-334.	1.0	6
85	Haploidentical cellular therapy in elderly patients with acute myeloid leukemia: Description of its use in high risk patients. American Journal of Hematology, 2013, 88, 720-721.	4.1	6
86	CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, S25-S26.	2.0	5
87	Beat pediatric ALL MRD: CD28 CAR T and transplant. Blood, 2019, 134, 2333-2335.	1.4	5
88	A short course of granulocyteâ€“colony-stimulating factor to accelerate wound repair in patients undergoing surgery for sacrococcygeal pilonidal cyst: proof of concept. Cytotherapy, 2012, 14, 1101-1109.	0.7	4
89	273. Genome Editing Using CRISPR-Cas9 to Increase the Therapeutic Index of Antigen-Specific Immunotherapy in Acute Myeloid Leukemia. Molecular Therapy, 2016, 24, S108.	8.2	4
90	Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies. Blood, 2014, 124, 966-966.	1.4	4

#	Article	IF	Citations
91	Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models. Blood, 2017, 130, 807-807.	1.4	4
92	Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas. Blood, 2021, 138, 1438-1438.	1.4	4
93	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1stâ€“2nd, 2021. Journal of Translational Medicine, 2022, 20, .	4.4	4
94	Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. Hematology American Society of Hematology Education Program, 2016, 2016, 432-436.	2.5	3
95	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. Blood, 2020, 136, 39-40.	1.4	3
96	Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia. Blood, 2016, 128, 1000-1000.	1.4	3
97	Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells. , 2015, 3, .		2
98	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. Biology of Blood and Marrow Transplantation, 2019, 25, 1387-1394.	2.0	2
99	Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors. Blood, 2020, 136, 30-30.	1.4	2
100	The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation.. Blood, 2007, 110, 1672-1672.	1.4	2
101	A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.. Blood, 2009, 114, 882-882.	1.4	2
102	The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies. Blood, 2021, 138, 253-253.	1.4	2
103	Antigen Glycosylation Is a Central Regulator of CAR T Cell Efficacy. Blood, 2021, 138, 1721-1721.	1.4	2
104	CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis. Blood, 2018, 132, 698-698.	1.4	1
105	Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,. Blood, 2011, 118, 3699-3699.	1.4	1
106	Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenstroì‹m Macroglobulinemia.. Blood, 2009, 114, 3434-3434.	1.4	1
107	Telomere Length In Ph - Negative Chronic Myeloproliferative Neoplasms: It Is Reduced According to JAK2 V617F Mutation Allele Burden and It Is Not Affected by Cytoreductive Treatment with Hydroxyurea. Blood, 2010, 116, 1975-1975.	1.4	1
108	Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors. Blood, 2021, 138, 2445-2445.	1.4	1

#	Article	IF	Citations
109	Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects. Blood, 2021, 138, 163-163.	1.4	1
110	Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.. Blood, 2007, 110, 3025-3025.	1.4	0
111	Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (ZevalinÂ®) with Autograft: Lack of Detection of Remarkable Abnormalities.. Blood, 2008, 112, 2158-2158.	1.4	0
112	The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.. Blood, 2010, 116, 1289-1289.	1.4	0
113	Pre-Operative Bone Marrow-Derived Cell Mobilization by G-CSF Enhances Osseointegration of Bone Substitute In Patients Undergoing Surgery with High Tibial Valgus Osteotomy. Blood, 2010, 116, 4773-4773.	1.4	0
114	Lenalidomide as Single Agent to Control Minimal Residual Disease in Chronic Lymphocytic Leukemia In First Complete Remission: Report of Three cases. Blood, 2010, 116, 4640-4640.	1.4	0
115	Exposure of Cultured Human Mesenchymal Stem Cells to Chemotherapy Induces An Early and Permanent Telomere Loss: Biological and Clinical Implications. Blood, 2010, 116, 4776-4776.	1.4	0
116	Early and Permanent Telomere Shortening in Bone Marrow-Derived Cells Following Chemotherapy: A Parallel Study In Vivo in Lymphoma Patients and In Vitro in Cultured Mesenchymal Stem Cells. Blood, 2011, 118, 1620-1620.	1.4	0
117	Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls?. Blood, 2012, 120, 4094-4094.	1.4	0
118	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma. Blood, 2015, 126, 704-704.	1.4	0
119	Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters. Translational Cancer Research, 2016, 5, S590-S594.	1.0	0
120	Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas. Blood, 2018, 132, 2959-2959.	1.4	0
121	A Novel Cotinine-Based System for Switchable Chimeric Antigen Receptor T Cell Immunotherapy. Blood, 2021, 138, 4803-4803.	1.4	0
122	A Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19. Blood, 2021, 138, 2798-2798.	1.4	0